Current Report Filing (8-k)
March 13 2017 - 8:54AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of
The Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): March 13, 2017
Sucampo Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware
|
001-33609
|
30-0520478
|
(State or other jurisdiction of
incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
805 King Farm Blvd, Suite 550
Rockville, Maryland 20850
(Address of principal executive offices, including zip code)
(301) 961-3400
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01. Regulation FD Disclosure.
On March 13, 2017, Sucampo Pharmaceuticals, Inc. (“Company”)
will make a corporate update presentation at one-on-one meetings with analysts and investors in New York at the 29
th
Annual Roth Conference. All meetings will include written communication comprised of slides. The slides from the presentation are
being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in the presentation furnished as Exhibit
99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), and is not incorporated by reference into any of the Company’s filings under the Securities
Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth
by specific reference in any such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit
Number
|
|
Exhibit Description
|
|
99.1
|
|
Presentation titled “Sucampo Pharmaceuticals, Inc. Corporate Update” dated March 13, 2017.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
SUCAMPO PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
/s/ Andrew P. Smith
|
|
Date: March 13, 2017
|
|
Name: Andrew P. Smith
|
|
Title: Chief Financial Officer
|
|
EXHIBIT INDEX
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Apr 2023 to Apr 2024